AIM: To study the effect of adenovirus (Ad)-p53 gene therapy on hepatocellular carcinoma (HCC) in a rabbit model. METHODS: VX2 tumor was grown in the liver of 24 rabbits. Animals were divided into four groups: group A receiving trans-arterial gene therapy (Ad-p53) only, group B receiving combined Ad-p53 therapy and trans-arterial embolization (lipiodol), group C receiving trans-arterial chemoembolization (lipiodol + mitomycin C), control group (D) receiving sodium chloride. Tumor volume (V1) was measured by using MRI (d 13). Interventional procedure was applied (d 14). Tumor volume (V2) was assessed by MRI (d 21) and the mean ratio (V2/V1) was calculated. After the second MRI, specimens of the liver were abstained and examined immunohistochemically using mutant-type p53 antibody. The positive expression was scored. RESULTS: Compared with control group (chi= 3.14 +/- 0.64), therapeutic groups all showed a significant decrease in the tumor growth ratio (P<0.05). A slight difference was found between group A (chi = 2.35 +/- 0.59) and group B (chi = 1.75 +/- 0.28) (P=0.048). No statistically significant difference was observed between group B and group C (chi = 2.00 +/- 0.44). The positive expression rate of mutant-type p53 was the lowest in group B and significantly different between group A and group C (P<0.05). Compared to the control subjects, groups A and C both showed a decrease in the expression of mutant-type p53, but there was no significant difference between them. CONCLUSION: Trans-arterial Ad-p53 gene therapy can reduce tumor growth of HCC in rabbit model.
AIM: To study the effect of adenovirus (Ad)-p53 gene therapy on hepatocellular carcinoma (HCC) in a rabbit model. METHODS: VX2 tumor was grown in the liver of 24 rabbits. Animals were divided into four groups: group A receiving trans-arterial gene therapy (Ad-p53) only, group B receiving combined Ad-p53 therapy and trans-arterial embolization (lipiodol), group C receiving trans-arterial chemoembolization (lipiodol + mitomycin C), control group (D) receiving sodium chloride. Tumor volume (V1) was measured by using MRI (d 13). Interventional procedure was applied (d 14). Tumor volume (V2) was assessed by MRI (d 21) and the mean ratio (V2/V1) was calculated. After the second MRI, specimens of the liver were abstained and examined immunohistochemically using mutant-type p53 antibody. The positive expression was scored. RESULTS: Compared with control group (chi= 3.14 +/- 0.64), therapeutic groups all showed a significant decrease in the tumor growth ratio (P<0.05). A slight difference was found between group A (chi = 2.35 +/- 0.59) and group B (chi = 1.75 +/- 0.28) (P=0.048). No statistically significant difference was observed between group B and group C (chi = 2.00 +/- 0.44). The positive expression rate of mutant-type p53 was the lowest in group B and significantly different between group A and group C (P<0.05). Compared to the control subjects, groups A and C both showed a decrease in the expression of mutant-type p53, but there was no significant difference between them. CONCLUSION: Trans-arterial Ad-p53 gene therapy can reduce tumor growth of HCC in rabbit model.
Authors: Alban L Denys; Thierry De Baere; Viseth Kuoch; Benoit Dupas; Patrick Chevallier; David C Madoff; Pierre Schnyder; Francesco Doenz Journal: Eur Radiol Date: 2003-08-27 Impact factor: 5.315
Authors: T Yoshida; M Sakon; K Umeshita; T Kanai; A Miyamoto; T Takeda; M Gotoh; H Nakamura; K Wakasa; M Monden Journal: J Clin Gastroenterol Date: 2001-01 Impact factor: 3.062
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li Journal: Am J Pathol Date: 2003-06 Impact factor: 4.307
Authors: L H Ramirez; Z Zhao; P Rougier; C Bognel; R Dzodic; G Vassal; P Ardouin; A Gouyette; J N Munck Journal: Cancer Chemother Pharmacol Date: 1996 Impact factor: 3.333
Authors: Aaron C Eifler; Robert J Lewandowski; Sumeet Virmani; Johnathan C Chung; Dingxin Wang; Richard L Tang; Barbara Szolc-Kowalska; Gayle E Woloschak; Guang-Yu Yang; Robert K Ryu; Riad Salem; Andrew C Larson; Eric Cheon; Matthew Strouch; David J Bentrem; Reed A Omary Journal: J Vasc Interv Radiol Date: 2009-06-28 Impact factor: 3.464